EZH2 and cancer: In additionto appraising the EED binding by TR-FRET assay, the most potent compoundswere also tested in cancer cell lines responsive to EZH2 inhibition(i.e., G-401 and OCILY cells) to assess the impairment of the H3K27trimethylation.